An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer-Reference-Cited by-同舟云学术

An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer

Published:2021-12 Issue:3 Volume:163 Page:473-480
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Liu Joyce,Burris Howard,Wang Judy S.,Barroilhet Lisa,Gutierrez Martin,Wang Yulei,Vaze Anjali,Commerford Renee,Royer-Joo Stephanie,Choeurng Voleak,Humke Eric,Moore Kathleen

Funder

Genentech

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference22 articles.

1. Cancer statistics;Jemal;CA Cancer J. Clin.,2010

2. Management of recurrent ovarian carcinoma: current status and future directions;Martin;Semin. Oncol.,2009

3. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer;Monk;J. Clin. Oncol.,2010

4. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial;Pujade-Lauraine;J. Clin. Oncol.,2014

5. Reactivity of a monoclonal antibody with human ovarian carcinoma;Bast;J. Clin. Invest.,1981

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research progress of antibody–drug conjugates in gynecologic cancer;Holistic Integrative Oncology;2024-08-29

2. Exploring the Role of Target Expression in Treatment Efficacy of Antibody–Drug Conjugates (ADCs) in Solid Cancers: A Comprehensive Review;Current Oncology Reports;2024-07-27

3. Ocular adverse events associated with antibody-drug conjugates for cancer: evidence and management strategies;The Oncologist;2024-07-24

4. Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data;Science Advances;2024-05-31

5. Drug resistance in ovarian cancer: from mechanism to clinical trial;Molecular Cancer;2024-03-28